Binosto
Product Images NDC 17139-400

6 FDA label images from Ascend Therapeutics · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Binosto (NDC 17139-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Therapeutics, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Alendronate Sodium 11 Description (B278a11a Alendronat Sodium Image 1)

Alendronate Sodium 11 Description (B278a11a Alendronat Sodium Image 1)
Chemical structure diagram of the active ingredient in Binosto, showing a sodium salt form with three water molecules (trihydrate). The structure includes phosphate groups and an amino-substituted carbon skeleton.*
FDA Label Image

Binosto 70mg Label (B278a11a Blister Label1)

Binosto 70mg Label (B278a11a Blister Label1)
Binosto 70 mg (alendronate sodium) effervescent tablet for oral solution packaging label. The label indicates a prescription product manufactured for ASCEND Therapeutics, Morristown, NJ, and states that the blister contains one complete week of treatment. NDC 17139-400-00 is visible on the label along with a barcode.*
FDA Label Image

Binosto 70mg Carton 4 Tablets (B278a11a Carton 041)

Binosto 70mg Carton 4 Tablets (B278a11a Carton 041)
Binosto 70 mg (alendronate sodium) effervescent tablet for oral solution packaging label. The label indicates a package containing 4 effervescent tablets, manufactured by Ascend Therapeutics, Morristown, NJ. The product is marked Rx only and includes storage instructions and a pharmacist attention notice regarding the medication guide.*
FDA Label Image

Figure 1 3 Yr Study (B278a11a Figure 1 Placebo 3 Year Study)

Figure 1 3 Yr Study (B278a11a Figure 1 Placebo 3 Year Study)
A line graph titled 'Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (Patients With Radiographic Vertebral Fracture at Baseline).' It compares cumulative incidence percentages over 36 months between two groups: placebo and alendronate sodium, with both showing increasing incidence over time but alendronate sodium lower than placebo.*
FDA Label Image

Figure 2 Osteoporosis (B278a11a Figure 2 Osteoporosis)

Figure 2 Osteoporosis (B278a11a Figure 2 Osteoporosis)
A bar graph titled 'Osteoporosis Treatment Studies in Postmenopausal Women Increase in BMD Alendronate Sodium 10 mg/day at Three Years.' It compares mean percentage increases in bone mineral density (BMD) relative to placebo at the lumbar spine, femoral neck, and trochanter for U.S. and multinational populations.*
FDA Label Image

Figure 3 Osteoporosis (B278a11a Figure 3 Osteoporosis)

Figure 3 Osteoporosis (B278a11a Figure 3 Osteoporosis)
Two line graphs comparing the effect of Alendronate Sodium 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change over 36 months in postmenopausal women. The left graph presents data from a U.S. study, and the right graph from a multinational study. Both show mean percent change in BMD from baseline with standard error over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.